Nastech Phase II nasal apomorphine data

NSTK said in a 184-patient Phase II trial, 82% of erectile dysfunction (ED) patients treated with 1 mg of its nasal apomorphine reported vaginal penetration (the primary endpoint), compared to 35% in ...